
Sign up to save your podcasts
Or


Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Vail Resorts (MTN) slid in postmarket trading Monday after the mountain resorts and hotels operator reported revenue for the second quarter that missed the average estimate. The company also cut its net income guidance for the full year.
- US airlines like United Airlines (UAL) and Southwest (LUV) quickly turned positive after President Donald Trump told CBS that the war in Iran could be over soon. Oil erased gains in after-settlement trading. Airlines were among several sectors that have been suffering losses amid the conflict in Iran.
- Hims & Hers (HIMS) surged after Novo Nordisk A/S was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform. Novo and Hims plan to announce a new partnership as soon as Monday, according to a person familiar with the matter, who spoke on the condition of anonymity. The two companies had a similar agreement last year, but Novo abruptly scrapped it after Hims refused to stop marketing and selling copycat medications.
See omnystudio.com/listener for privacy information.
By iHeartPodcasts4.6
1919 ratings
Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Vail Resorts (MTN) slid in postmarket trading Monday after the mountain resorts and hotels operator reported revenue for the second quarter that missed the average estimate. The company also cut its net income guidance for the full year.
- US airlines like United Airlines (UAL) and Southwest (LUV) quickly turned positive after President Donald Trump told CBS that the war in Iran could be over soon. Oil erased gains in after-settlement trading. Airlines were among several sectors that have been suffering losses amid the conflict in Iran.
- Hims & Hers (HIMS) surged after Novo Nordisk A/S was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform. Novo and Hims plan to announce a new partnership as soon as Monday, according to a person familiar with the matter, who spoke on the condition of anonymity. The two companies had a similar agreement last year, but Novo abruptly scrapped it after Hims refused to stop marketing and selling copycat medications.
See omnystudio.com/listener for privacy information.

406 Listeners

1,168 Listeners

2,194 Listeners

1,986 Listeners

419 Listeners

1,036 Listeners

1,307 Listeners

62 Listeners

59 Listeners

154 Listeners

84 Listeners

78 Listeners

76 Listeners

8 Listeners

11 Listeners